5-ethyl-1-methyl-5-phenyl-1,3-diazinane-2,4,6-trione

• ChemBase编号: 727
• 分子式: C13H14N2O3
• 平均质量: 246.26186
• 单一同位素质量: 246.10044232
• SMILES: O=C1N(C(=O)NC(=O)C1(CC)c1ccccc1)C
• Canonical SMILES: CCC1(C(=O)NC(=O)N(C1=O)C)c1ccccc1
• InChI: InChI=1S/C13H14N2O3/c1-3-13(9-7-5-4-6-8-9)10(16)14-12(18)15(2)11(13)17/h4-8H,3H2,1-2H3,(H,14,16,18)
• InChIKey: ALARQZQTBTVLJV-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 5-ethyl-1-methyl-5-phenyl-1,3-diazinane-2,4,6-trione
• IUPAC传统名: methylphenobarbital; mephobarbital; 5-ethyl-1-methyl-5-phenyl-1,3-diazinane-2,4,6-trione
• 商标名: Enfenemal; Enphenemal; Enphenemalum; Isonal; Mebaral; Meberal; Mebroin; Menta-Bal; Mephytal; Methyl-Calminal; Metylfenemal; Metyna; Morbusan; Phemetone; Phemiton; Phemitone; Phenmiton; Prominal
• 别名: 5-Ethyl-1-methyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione; 5-Ethyl-1-methyl-5-phenylbarbituric Acid; 5-Phenyl-5-ethyl-3-methylbarbituric Acid; Mebaral; Phemiton; Prominal; Mephobarbital; Mephobarbital; Mephobarbitone; Methyl Phenobarbitone; Methylphenobarbitalum [INN-Latin]; Methylphenobarbitonum; Methylphenolbarbital; Methylphenylbarbituric acid; Metilfenobarbital [INN-Spanish]; Metilfenobarbitale [Dcit]; N-Ethylmethylphenylbarbituric acid; N-Methylethylphenylbarbituric acid; N-Methylphenobarbital; N-Methylphenolbarbitol; Methylphenobarbital; Methylphenobarbitone; Enfenemal; Enphenemal; Mefobarbital; Mentabal; Phemitone; Methylphenobarbital

登记号

• CAS号: 115-38-8
• PubChem SID: 46505197; 160964190
• PubChem CID: 8271
• CHEBI ID: 6758
• ATC码: N03AA01
• CHEMBL: 45029
• Chemspider ID: 7972
• DrugBank ID: DB00849
• KEGG ID: D00700
• 美国药典/FDA物质标识码: 5NC67NU76B
• 维基百科标题: Methylphenobarbital
• Medline Plus: a605022

理论计算性质

JChem

• Acid pKa: 8.399005
• 质子受体: 3
• 质子供体: 1
• LogD (pH = 5.5): 1.6294647
• LogD (pH = 7.4): 1.5890191
• Log P: 1.6300062
• 摩尔折射率: 64.643 cm^3
• 极化性: 25.007318 Å^3
• 极化表面积: 66.48 Å^2
• 可自由旋转的化学键: 2
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 1.95
• LOG S: -2.54
• 溶解度: 7.10e-01 g/l

分子性质

理化性质

• 溶解度: DMSO; Methanol; Slightly soluble
• 外观: White Solid
• 熔点: 175-1770C
• 疏水性(logP): 1.84 [HANSCH,C ET AL. (1995)]

安全信息

• 保存条件: Controlled Substance, -20°C Freezer

药理学性质

• 半衰期: 34 hours
• 代谢: Hepatic
• 蛋白结合率: 70-76%
• 法定药品分级: Class B (UK); Schedule IV (US)
• 生物活性机理: Binds brain tissue protein; Binds plasma-protein; Dose-dependent respiratory depressant; Produces all levels of CNS mood alteration

产品相关信息

• 应用领域: Analgesic; Anticonvulsant; Antispasmodic; Sedative

详细说明

DrugBank - DB00849

• Drug Groups: approved
• Description: A barbiturate that is metabolized to phenobarbital. It has been used for similar purposes, especially in epilepsy, but there is no evidence mephobarbital offers any advantage over phenobarbital. [PubChem]
• Indication: For the relief of anxiety, tension, and apprehension, also used as an anticonvulsant for the treatment of epilepsy.
• Pharmacology: Methylphenobarbital, a barbiturate, is used in combination with acetaminophen or aspirin and caffeine for its sedative and relaxant effects in the treatment of tension headaches, migraines, and pain. Barbiturates act as nonselective depressants of the central nervous system (CNS), capable of producing all levels of CNS mood alteration from excitation to mild sedation, hypnosis, and deep coma. In sufficiently high therapeutic doses, barbiturates induce anesthesia.
• Affected Organisms: Humans and other mammals
• Biotransformation: Hepatic, primarily by the hepatic microsomal enzyme system. About 75% of a single oral dose of mephobarbital is metabolized to phenobarbital in 24 hours.
• Absorption: Approximately 50% of an oral dose of mephobarbital is absorbed from the gastrointestinal tract.
• Half Life: 34 (range 11-67) hours
• Protein Binding: 70-76%
• External Links: Wikipedia; RxList

Toronto Research Chemicals - M225020

Controlled substance (depressant). Anticonvulsant; sedative; hypnotic.

参考文献

• Price, W.C., et al.: J. Pharm. Pharmacol., 6, 522 (1954)
• Brochman-Hanssen, E., et al.: J. Pharm. Sci., 58, 370 (1954)
• Lackner, H., et al.: Arch. Toxikol., 26, 220 (1954)
• U.K. Pat., 1929, 339 937; CA, 25, 2738, (synth)
• Advovich, H.W. et al., Can. J. Pharm. Sci., 1969, 4, 51, (pmr)
• Craig, C.R. et al., J. Pharmacol. Exp. Ther., 1971, 176, 35, (pharmacol)
• Knabe, J. et al., Arch. Pharm. (Weinheim, Ger.), 1972, 305, 54, (synth)
• Saferstein, R. et al., J. Assoc. Off. Anal. Chem., 1973, 56, 1234, (ms)
• Dilli, S. et al., Aust. J. Chem., 1975, 28, 2265, (synth)
• Siek, T.J. et al., J. Forensic Sci., 1975, 20, 18, (uv)
• Asada, S. et al., Bull. Chem. Soc. Jpn., 1978, 51, 3379, (cmr)
• Hooper, W.D. et al., Ther. Drug Monit., 1981, 3, 39, (metab)
• Negwer, M., Organic-Chemical Drugs and their Synonyms, 6th edn., Akademie-Verlag, 1987, 2742, (synonyms)
• Murata, M. et al., Chem. Pharm. Bull., 1992, 40, 2605, (synth, R-form)
• Martindale, The Extra Pharmacopoeia, 30th edn., Pharmaceutical Press, 1993, 301
• Lewis, R.J., Sax's Dangerous Properties of Industrial Materials, 8th edn., Van Nostrand Reinhold, 1992, ENB500